Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis

European Cytokine Network

Volumn 8, Issue 3, 1997, Pages 253-257

  Chofflon, Michel ^a   Roth, Serge ^a   Juillard, Catherine ^a   Paunier, Anne Marie ^a   Juillard, Pierre ^c   Degroote, Didier ^b   Grau, Georges E ^c  

^a Hôpital Cantonal   (Switzerland)

^b Medgenix Diagnostics SA   (Belgium)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Marker; Multiple sclerosis; Sensitivity; Specificity; Tumor necrosis factor; Whole blood test

Indexed keywords

ANTIGEN; CYTOKINE; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR;

ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; DISEASE ACTIVITY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOLOGICAL MONITORING; LEUKOCYTE; MULTIPLE SCLEROSIS; PATHOGENESIS; RELAPSE; REMISSION;

CASE-CONTROL STUDIES; EVALUATION STUDIES; HUMANS; LEUKOCYTES; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PHYTOHEMAGGLUTININS; RECURRENCE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030830240     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Miller D H, Albert P S, Barkhof F, et al. 1996. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann. Neurol. 39: 6.
2. Selmaj K W, Raine C S. 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23: 338.
3. Powell M B, Mitchell D, Ledermen J, et al. 1990. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int. Immunol. 2: 539.
4. Ruddle N H, Bergman C M, McGrath K M, et al. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172: 1193.
5. Cannella B., Cross A H, Raine C S. 1990. Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system. J. Exp. Med. 172: 1521.
6. Brosnan C F, Cannella B, Battistini L, Raine C S. 1995. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 45: S16.
7. Cannella B, Raine C S. 1995. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37: 424.
8. Sharief M K, Thompson E J. 1992. In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. J. Neuroimmunol. 38: 27.
9. Rentzos H, Nikolaou C, Rombos A, Voumvourakis K, Segditsa I, Papageorgiou C. 1996. Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies. J. Neurol. 243: 165.
10. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. 1988. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 78: 318.
11. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau G E. 1992. Predictive value of TKF production in patients with multiple sclerosis. Eur. Cytokine Netw. 3: 523.
12. Glabinski A, Mirecka M, Pokoca L. 1995. Tumor necrosis factor alpha but not lymphotoxin is overproduced by blood mononuclear cells in multiple sclerosis. Acta Neurol. Scand. 91: 276.
13. Zangerle P F, Degroote D, Lopez M, et al. 1992. Direct stimulation of cytokines (IL-1beta, TNF-alpha, IL-6, IFN-gamma and GM-CSF) in whole blood. 2. Application to rheumatoid arthritis and osteoarthritis. Cytokine 4: 568.
14. Dahlke E, Schlag R, Langenmayer I, et al. 1995. Decreased production of TNF and IL-6 in whole blood of CLL patients. Am. J. Hematol. 49: 76.
15. Fabian T C, Croce M A, Fabian M J, et al. 1995. Reduced tumor necrosis factor production in endotoxin-spiked whole blood after trauma: experimental results and clinical correlation. Surgery 118: 63.
16. Marchant A, Deviere J, Byl B, Degroote D, Vincent J L, Goldman M. 1994. Interleukin-10 production during septicaemia. Lancet 343: 707.
17. Ertel W, Kremer J P, Kenney J, et al. 1995. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85: 1341.
18. Westendorp R G, Langermans J A, de Bel C E, et al. 1995. Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J. Infect. Dis. 171: 1057.
19. Yentis S M, Soni N, Riches P G. 1994. In vitro effects of HA-1A (Centoxin) on cytokine production in whole blood from intensive care unit patients. Br. J. Anaesth. 73: 805.
20. Kremsner P G, Winkler S, Brandt C, et al. 1995. Elevated capacity of tumor necrosis factor production predicts accelerated cure in patients with Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg. 53: 532.
21. Engelberts I, Francot G J M, Leunissen K M L, et al. 1994. Effect of hemodialysis on peripheral blood monocyte tumor necrosis factor-alpha, interleukin-6, and interleukin-8 secretion in vitro. Nephron 66: 396.